Category: Derma Sciences Inc.Syndicate content

Derma Sciences losses widen, sales increase in Q3

November 13, 2013 by Arezu Sarvestani

Wound care company Derma Sciences posted a 12.7% boost in sales for its 3rd quarter, as well as a 62% increase in losses.

Derma Sciences lossed widen, sales increase in Q3

Derma Sciences (NSDQ:DSCI) got a little bit of attention from Wall Street today, with shares up a modest 0.6% in late afternoon trading following release of the company's Q3 earnings.

SEC dings Deerfield Capital Management $2M for short-selling violations

September 17, 2013 by Brad Perriello

Deerfield Capital Management agrees to pay nearly $2 million to the SEC for short-selling violations involving Insulet, Derma Sciences, TearLab and other life science stocks.

SEC dings Deerfield Management $2M for short-selling violations

Second-quarter losses soar for Derma Sciences

August 12, 2013 by Sony Salzman

Wound care company Derma Sciences sinks deeper into the red in the 2nd quarter, but beats Wall Street's expectations by 4¢.

Derma Sciences

Second-quarter losses soared for Derma Sciences (NSDQ:DSCI), but the wound care company still managed to beat Wall Street's earnings expectations by 4¢.

Princeton, N.J.-based Derma Sciences reported losses of $7.3 million, or 43¢ per share, on sales of $18.1 million for the 3 months ended June 30. Losses grew 59.8% despite a 3.1% top-line gain, compared with Q2 2012.

Derma Sciences skins out $36M

December 12, 2012 by MassDevice staff

Derma Sciences raises $36 million closes a $36 million public stock offering it plans to use to continue development on its lead drug candidate for diabetic foot ulcers.

Derma Sciences

Derma Sciences (NSDQ:DSCI) said it's closed an offering of some 3.5 million shares of its stock at $10.34 apiece.

The Princeton, N.J.-based medical device company said it plans to use the $33.8 million in net proceeds from the $36.4 million offering to further develop its lead drug candidate DSC127.

Derma Sciences said the drug is being designed to treat chronic diabetic foot ulcers.

Derma Sciences CEO Quilty's resignation from board appeases Nasdaq | Wall Street Beat

July 5, 2012 by MassDevice staff

Derma Sciences president & CEO Edward Quilty resigns from the company's board of directors after Nasdaq's listing qualifications officers noted that his membership was in violation of listing rules. Wall Street Beat

Derma Sciences (NSDQ:DSCI) president & CEO Edward Quilty resigned from the company's board of directors, settling a non-compliance issue that could have led to delisting from the Nasdaq stock exchange.

Stryker to begin New York layoffs ahead of the medical device tax | Wall Street Beat

June 25, 2012 by MassDevice staff

Stryker's plans to cut more than 100 jobs by closing 2 New York manufacturing facilities will begin in September and continue on a rolling basis until the end of the year, just ahead of implementation of the 2.3% medical device tax. Wall Street Beat

Stryker (NYSE:SYK) is making good on plans to cut more than 100 positions by closing 2 New York manufacturing plants, moves that the company previously attributed to attempts to cut costs ahead of the coming 2.3% medical device tax.